Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An enzyme-linked oligonucleotide assay

D W Drolet1, L Moon-McDermott, T S Romig

  • 1NeXstar Pharmaceuticals, Boulder, CO 80301, USA. ddrolet@nexstar.com

Nature Biotechnology
|August 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the efficacy of amikacin in low-clearance unilamellar liposomes in a s. Aureus local infection model.

Journal of liposome research·2009
Same author

Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.

British journal of cancer·2006
Same author

A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.

Cancer chemotherapy and pharmacology·2006
Same author

Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys.

Pharmaceutical research·2001
Same author

Bioavailability of a small unilamellar low-clearance liposomal amikacin formulation after extravascular administration.

Journal of drug targeting·2000
Same author

Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.

Clinical cancer research : an official journal of the American Association for Cancer Research·2000
Same journal

Unlocking the chemical potential of filamentous fungi using prime editing.

Nature biotechnology·2026
Same journal

A genome-scale CRISPRi perturbation atlas of human induced pluripotent stem cells.

Nature biotechnology·2026
Same journal

Prime editing for precise genome engineering and modulation of fungal metabolism.

Nature biotechnology·2026
Same journal

Retargeted serine integrases for one-step, precise integration of large DNA sequences in human cells.

Nature biotechnology·2026
Same journal

A retargeted recombinase for precise insertion of large DNA.

Nature biotechnology·2026
Same journal

Experiment-guided AlphaFold3 resolves measurement-consistent protein ensembles.

Nature biotechnology·2026
See all related articles

Systematic Evolution of Ligands by Exponential Enrichment (SELEX) identifies high-affinity oligonucleotide ligands. These SELEX-derived oligonucleotides prove effective as analytical reagents in novel enzyme-linked assays.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Analytical Chemistry

Background:

  • Combinatorial chemistry offers a pathway to novel therapeutic and diagnostic reagents.
  • Systematic Evolution of Ligands by Exponential Enrichment (SELEX) is a powerful in vitro method for identifying high-affinity ligands.
  • Oligonucleotides selected via SELEX hold potential as specific binding agents.

Purpose of the Study:

  • To demonstrate the utility of SELEX-derived oligonucleotides as analytical reagents.
  • To develop and validate an enzyme-linked sandwich assay utilizing a SELEX-selected oligonucleotide.
  • To showcase the effectiveness of SELEX technology in generating functional diagnostic tools.

Main Methods:

  • Utilized Systematic Evolution of Ligands by Exponential Enrichment (SELEX) to select high-affinity oligonucleotide sequences from large random pools.

Related Experiment Videos

  • Developed an enzyme-linked sandwich assay incorporating a SELEX-derived oligonucleotide as a key component.
  • Validated the performance of the assay in detecting target molecules.

    • Main Results:

    • Successfully identified specific oligonucleotide sequences with high binding affinity and specificity for a target molecule using SELEX.
    • The developed enzyme-linked sandwich assay demonstrated the practical application of these SELEX-derived oligonucleotides.
    • The assay confirmed the effectiveness and utility of these oligonucleotides as analytical reagents.

    Conclusions:

    • SELEX is a robust method for generating high-affinity oligonucleotide ligands.
    • SELEX-derived oligonucleotides are valuable and effective reagents for analytical applications.
    • The developed enzyme-linked assay represents a significant advancement in diagnostic reagent development.